Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 19

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 19
---
 Shares following such exercise, excluding for purposes of such determination Ordinary Shares issuable
upon exercise of such warrants which have not been exercised. The beneficial ownership limitation may be increased or decreased, provided
that in no event shall it exceed 9.99%, upon notice to us, provided that any increase in the beneficial ownership limitation shall not
be effective until 61 days following the receipt of such notice by us. The number of shares in the table below does not reflect this
limitation. See “Plan of Distribution.” The selling shareholders may sell all, some or none of their Ordinary Shares
in this offering. See “Plan of Distribution.”

| Name of Selling Shareholder     |     | Number of Ordinary    
 Shares Owned Prior to 
 Offering              |             |     | Maximum Number of             
 Ordinary Shares to be Sold    
 Pursuant to this Prospectus * |            |     | Number of Ordinary 
 Shares Owned After 
 Offering (1)       |             |
| Bigger Capital Fund, LP (2)*    |     |                       | 468,000,000 |     |                               | 81,100,000 |     |                    | 386,900,000 |
| District 2 Capital Fund LP (3)* |     |                       | 484,500,000 |     |                               | 90,600,000 |     |                    | 393,900,000 |

________________

*Subject to beneficial ownership blocker of 9.99%.

| (1) | Assumes that all Ordinary Shares                                                             
 being registered under the registration statement of which this prospectus forms a part are  
 sold in this offering, and that none of the selling stockholders acquire additional Ordinary 
 Shares after the date of this prospectus and prior to completion of this offering.           |

| (2) | The selling shareholder                                                                             
 holds (i) warrants issued by us in prior transactions which entitle the selling shareholder         
 to purchase an aggregate of 386,900,000 Ordinary Shares (in the form of Depositary Shares),         
 and (ii) December 2023 Private Placement Pre-Funded Warrants, which entitle the selling shareholder 
 to purchase an aggregate of 81,100,000 Ordinary Shares (in the form of Depositary Shares)           
 and which we are registering hereby. The warrants are subject to a beneficial ownership limitation  
 of 9.99%, which does not permit the selling shareholder to exercise that portion of the warrants    
 that would result in the selling shareholder and its affiliates owning, after exercise, a